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Thyroid hormone plays a pivotal role in human metabolism. In epidemiologic studies, ade-
quate registration of thyroid disorders is warranted. We examined the prevalence of thyroid
disorders, reported thyroid medication use, thyroid hormone levels, and validity of thyroid
data obtained from questionnaires in the Lifelines Cohort Study.
Methods
We evaluated baseline data of all 152180 subjects (aged 18–93 years) of the Lifelines
Cohort Study. At baseline, participants were asked about previous thyroid surgery and cur-
rent and previous thyroid hormone use. At follow-up (n = 136776, after median 43 months),
incident thyroid disorders could be reported in an open, non-structured question. Data on
baseline thyroid hormone measurements (TSH, FT4 and FT3) were available in a subset of
39935 participants.
Results
Of the 152180 participants, mean (±SD) age was 44.6±13.1 years and 58.5% were female.
Thyroid medication was used by 4790 participants (3.1%); the majority (98.2%) used
levothyroxine, and 88% were females. 59.3% of levothyroxine users had normal TSH levels.
The prevalence of abnormal TSH levels in those not using thyroid medication was 10.8%;
9.4% had a mildly elevated (4.01–10.0 mIU/L), 0.7% had suppressed (<0.40 mIU/L), while
0.7% had elevated (>10.0 mIU/L) TSH levels. Over 98% of subjects with TSH between 4
and 10 mIU/L had normal FT4. Open text questions allowing to report previous thyroid sur-
gery and incident thyroid disorders proved not to be reliable and severely underestimated
the true incidence and prevalence of thyroid disorders.
Conclusions
Undetected thyroid disorders were prevalent in the general population, whereas the preva-
lence of thyroid medication use was 3.1%. Less than 60% of individuals using levothyroxine
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had a normal TSH level. The large group of individuals with subclinical hypothyroidism
(9.4%) offers an excellent possibility to prospectively follow the natural course of this disor-
der. Both structured questions as well as linking to G.P.’s and pharmacists’ data are neces-
sary to improve the completeness and reliability of Lifelines’ data on thyroid disorders.
Introduction
Thyroid hormone plays a pivotal role in human metabolism. It is important in all processes in
the body, including metabolic pathways, growth, development, cognition, energy homeostasis
and temperature regulation. Peripheral thyroid hormone levels are closely regulated by the
pituitary gland. Disorders of thyroid function are frequently diagnosed, with prevalences vary-
ing between 2 and 6% in large population-based studies [1–3].
Thyroid disorders and their treatment may have a great impact on long-term health. Thyro-
toxicosis and even mild (subclinical) hyperthyroidism are associated with a higher risk of car-
diovascular problems and osteoporosis [4–7], while hypothyroidism has been associated with
dyslipidaemia, atherosclerosis and also an increased risk of cardiovascular events [8–11]. Over-
substitution of levothyroxine in individuals with a thyroid disorder accounted for approxi-
mately half of both prevalent and incident suppressed thyroid stimulating hormone (TSH)
findings in a community-based cohort, especially among older women, which increases their
risk of atrial fibrillation and osteoporosis [12]. In order to assess the (life-time) consequences
of mild thyroid dysfunction and thyroid disorders in epidemiologic studies, adequate registra-
tion of such disorders, the use of medication influencing thyroid function, and degree of con-
trol of thyroid dysfunction is necessary. Hypothyroidism may not be readily recognized, or
remain even asymptomatic for a -yet unknown- period [3, 13], leading to a longer exposure to
low thyroid hormone levels. More severe suppression of TSH in individuals treated for hypo-
thyroidism and thyroid cancer has been associated with a higher incidence of cardiovascular
events and osteoporosis [14, 15].
Biobanks offer the unique possibility to retrieve earlier serum samples to evaluate preceding
thyroid hormone levels, especially when repeated evaluation and sample collection in their
participants is performed. The Lifelines Cohort Study is such a biobank, examining in a unique
three-generation design the health and health-related behaviours of the habitants in the North
of the Netherlands. In this study, we examine the prevalence of thyroid disorders, thyroid hor-
mone use, and thyroid hormone levels in the Lifelines Cohort Study. Results are compared
with similar data obtained in other population-based studies and in the Dutch G.P. morbidity
registry for validation purposes.
Materials and methods
Participants
Subjects included were participants in the Lifelines Cohort Study, a multi-disciplinary prospec-
tive population-based cohort study examining in a unique three-generation design the health
and health-related behaviours of 167729 persons living in the North of The Netherlands. It
employs a broad range of investigative procedures in assessing the biomedical, socio-demo-
graphic, behavioural, physical and psychological factors which contribute to the health and dis-
ease of the general population, with a special focus on multi-morbidity and complex genetics
[16–18]. It was demonstrated that the Lifelines adult study population is broadly representative
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for the adult population of the North of the Netherlands [19]. All participants have provided
written informed consent before participating in the study, which has been approved by the
Medical Ethics Review Committee of the University Medical Center Groningen.
For the present study, we evaluated the data of all 152180 subjects between 18 and 93 years of
age who underwent a baseline examination between January 2007 and December 2013. In addi-
tion, follow-up data which have been collected between January 2014 and January 2017 were
available for analysis in 136776 participants. Of these, 98626 had filled in follow-up questionnaires
and underwent follow-up measurements, while in 38150 only interim questionnaire data were
available. Median follow-up until the last questionnaire was 43 months (range 11 to 133 months).
Measurement of thyroid hormone levels, i.e. TSH, free thyroxine (FT4) and free triiodothy-
ronine (FT3), started in November 2009. As Lifelines decided to stop the measurement of thy-
roid hormones in November 2011, these measurements were only available and complete in a
subset of 39935 participants. There was no clinically relevant difference in sex distribution, age
and body mass index (BMI) between those with and without thyroid hormone levels mea-
sured. In 37741 of these 39935 participants, follow-up data were available. Of these, 30050 had
filled in follow-up questionnaires and underwent follow-up measurements, while in 7691 only
interim questionnaire data were available. Median follow-up in this subgroup was 48 months
(range 12 to 112 months).
Questionnaires and clinical examination
The specific methodology employed by Lifelines has been described previously [17, 20, 21]. At
both baseline and follow-up examination, participants completed a self-administered ques-
tionnaire on medical history and past and current diseases. The catalogue of these question-
naires can be browsed at https://www.lifelines.nl. A limited number of participants (3%) was
not able to fill in the questionnaires themselves; for those participants a proxy questionnaire
was used and filled in by a close relative. The proxy questionnaire was considerably shorter
than the full questionnaires. Questions related to thyroid disorders have been summarised in
Table 1. During the baseline examination, participants were asked about current and previous
use of medication for a thyroid disorder (HEALTH66/67), and concomitant thyroid disorders
(HEALTH73). Previous thyroid surgery (HEALTH74) could be reported by participants in an
open, non-structured question. During follow-up, no structured questions regarding thyroid
disorders or medication use were asked, therefore incident thyroid disorders were based on
self-report obtained from an open, non-structured question (HEALTH100).
Table 1. Content of the questionnaires.
Question# Description in the questionnaire
Baseline
HEALTH66 Do you currently use medication for an overactive or underactive thyroid? Yes / No
HEALTH67 Have you used medication for an overactive or underactive thyroid in the past? Yes / No
HEALTH73 Do you have or have you had another disorder that you have not mentioned yet? Yes / No
If you have had another disorder, what disorder? Open text
answer
HEALTH74 If you ever had surgery, what was the reason for the surgery? Open text
answer
Follow-up#
HEALTH100 Could you indicate which other health problems you have (had) since the last time
you filled out this questionnaire?
Open text
answer
# once every 1.5 years.
https://doi.org/10.1371/journal.pone.0242795.t001
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Medication use was verified at baseline by a certified research assistant, and scored by the
Anatomical Therapeutic Chemical (ATC) Classification System, a system developed for the
classification of active ingredients of drugs. We discriminated between the use of levothyrox-
ine (ATC code H03AA01), liothyronine (ATC H03AA02), and thyroid blockers (methimazol
or propylthiouracil, ATC code H03BA and H03BB). For most evaluations, we excluded 60 par-
ticipants using amiodarone (ATC code C01BD01), as this drug may significantly alter thyroid
hormone levels [22]. Structured ascertainment of thyroid disorders or medication use by Life-
lines participants with the use of other sources, like general practitioners’ or pharmacists’ data,
was not performed.
A standardised protocol was used to obtain blood pressure and anthropometric measure-
ments: height, weight, and waist circumference. Weight was measured to the nearest 0.1 kg
and height and waist circumference to the nearest 0.5 cm by the research assistant using cali-
brated measuring equipment, with participants wearing light clothing and no shoes. Waist cir-
cumference was measured with a tape around the body between the lower rib margin and the
iliac crest. BMI was calculated as weight divided by height squared (kg/m2). Systolic and dia-
stolic blood pressure (BP) and heart rate were measured every minute for 10 minutes in the
supine position using an automated Dinamap Monitor (GE Healthcare, Freiburg, Germany).
The average of the last three readings was recorded for each blood pressure parameter and
heart rate.
Prevalence and incidence comparison with other sources
For comparison with Lifelines epidemiologic data, we have assessed the prevalence of hypothy-
roidism (International Classification of Primary Care (ICPC) T86) as collected by NIVEL
(Netherlands Institute for Health Services Research) through registration by G.P.’s. This public
dataset was created in March 2014, and comprised data on incidence and prevalence of hypo-
thyroidism during the year 2013.
Our second source for comparison was NHANES, a cross-sectional survey in the USA that
uses a complex, stratified, multistage sampling design [23, 24]. We used data from NHANES
2007–2008, 2009–2010 and 2011–2012 participants who were aged 18 years and above, and had
serum TSH measurements available (n = 9209). Written informed consent was obtained from
all participants; the survey protocol was approved by the Research Ethics Review Board of the
National Center for Health Statistics. Interviews, examination response rates, methodology and
results are publicly available [25]. Hypothyroidism was defined as the use of levothyroxine.
Biochemical measurements
Blood samples were taken in the fasting state between 8:00 and 10:00 a.m. and transported to
the laboratory facility at room temperature or 4˚C, depending on the sample requirements. All
measurements were performed the same day. Levels of TSH, FT4 and FT3 were assayed by
electrochemiluminescence immunoassay (Roche Modular E170, Roche, Switzerland). Gly-
cated haemoglobin (HbA1c, EDTA-anticoagulated) was analysed using an NGSP-certified tur-
bidimetric inhibition immunoassay on a Cobas Integra 800 CTS analyser (Roche Diagnostics
BV, Almere, The Netherlands). Serum creatinine was measured on a Roche Modular P chem-
istry analyser (Roche, Basel, Switzerland). Total and high density lipoprotein (HDL) choles-
terol were measured using an enzymatic colorimetric method, triglycerides using a
colorimetric UV method, and low density lipoprotein (LDL) cholesterol using an enzymatic
method, on a Roche Modular P chemistry analyser (Roche, Basel, Switzerland). Fasting blood
glucose was measured using a hexokinase method. The general Dutch population is iodine suf-
ficient [26]. Anti-thyroid peroxidase antibody levels were not available.
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Definitions of concomitant morbidities, calculations, and statistical
analyses
Diagnosis of metabolic syndrome was established if a subject satisfied at least three out of five
criteria according to the modified guidelines of the National Cholesterol Education Programs
Adults Treatment Panel III (NCEP ATPIII criteria): 1. systolic blood pressure�130 mmHg
and/or diastolic blood pressure�85 mmHg and/or use of antihypertensive medication; 2.
HDL cholesterol levels <1.03 mmol/L in men and<1.30 mmol/L in women and/or use of
lipid-lowering medication influencing HDL levels; 3. triglyceride levels�1.70 mmol/L and/or
use of triglyceride-lowering medication; 4. waist circumference�102 cm in men and�88 cm
in women; 5. fasting glucose level� 5.6 mmol/L and/or use of blood glucose-lowering medica-
tion and/or diagnosis of type 2 diabetes [27]. Diagnosis of type 2 diabetes was by self-report,
use of oral blood-glucose-lowering agents or insulin, or a fasting blood glucose� 7.0 mmol/L,
and/or a HbA1c� 6.5% at baseline laboratory evaluation. Use of statins and blood-pressure-
lowering drugs was assessed based on the ATC codes of verified medication use (statins: ATC
code C10AA��; BP-lowering drugs: ATC codes C02�, C03�, C04�, C07�, C08�, C09�).
We cross-tabulated verified medication use with the answers to questions HEALTH66 and
HEALTH67 (self-reported current and previous use of medication for a thyroid disorder,
Table 2). The percentage of users of thyroid hormone medication were calculated per age
group for the entire cohort. In those participants with available thyroid hormone measure-
ments, mean levels of TSH, FT4 and FT3 were calculated according to the use of levothyroxine.
For these calculations, participants using liothyronine and thyroid hormone blockers were
excluded. Participants were divided into subgroups according to serum TSH values (1st: sup-
pressed, TSH <0.40 mIU/L; 2nd: euthyroid, TSH 0.40–4.0 mIU/L (reference group); 3rd:
mildly elevated, TSH 4.01–10.0 mIU/L, also defined as subclinical hypothyroidism; 4th:
markedly elevated, TSH >10.0 mIU/L, overt hypothyroidism). The percentage of users of thy-
roid hormone and distribution of TSH class was calculated for all age-decade groups (18–29,
30–39, 40–49, 50–59, 60–69, 70–79,�80 years). For comparison of Lifelines with NIVEL and
NHANES data, the prevalence of thyroid hormone use was calculated for the age groups 18–
44, 45–64, 65–74, 75–84, and�85 years, since these were the age groups used by NIVEL. Local
laboratory reference values for FT4 were 11–20 pmnol/L, for FT3 4.4–6.7 pmol/L.
All answers to the open questions HEALTH73, HEALTH74 and HEALTH100 which were
related to thyroid disorders were scored according to the most likely diagnosis or reason for
surgery: 1. Hypothyroidism; 2. Hyperthyroidism not specified; 3. Graves’ disease; 4. Nodular
disease or goiter; 5. Thyroid cancer; 6. Thyroiditis; 7. Thyroid disorder not specified.
Table 2. Current use of medication for a thyroid disorder (question HEALTH66).
Yes No Missing Total
Are you currently using medication for a thyroid disorder? 4579 (3.0%) 143870 (94.5%) 3731 (2.5%) 152180
Cross-check with medication overview list
Levothyroxine 4416 (96.4%) 56 (<0.1%) 231 (6.3%) 4703
Liothyronine 68 (1.5%) <10 (<0.1%) 0 (0%) n.a.
Thyroid blocker 106 (2.3%) <10 (<0.1%) <10 (<0.1%) n.a.
Animal source of thyroid hormone 19 (0.4%) <10 (<0.1%) <10 (<0.1%) n.a.
Any of the above� 4491 (98.1%) 63 (0.04%) 236 (6.3%) 4790
No medication used / reported 88 (1.9%) 143807 (>99%) 3495 (93.7%) 147390
� a participant could use one or more of these medications.
https://doi.org/10.1371/journal.pone.0242795.t002
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All analyses were conducted using SPSS Statistics (Version 22, IBM, Armonk, NY, USA).
Data are presented as mean ± SD, or median and IQR (interquartile range) when not normally
distributed, or percentages. Means were compared between groups with analysis of variance.
When variables were not normally distributed, medians were compared with the nonparamet-
ric Mann-Whitney U test. Chi-square test was used to analyse categorical variables. P-
values< 0.05 were considered statistically significant.
Results
Baseline dataset
S1 Table shows the most relevant baseline parameters for the participants according to
levothyroxine use. Of the 152180 participants, 89050 (58.5%) were female. Mean age was 44.6
(SD 13.1, range 18–93) years, and mean BMI was 26.1 (SD 4.3, range 13.4–73.6) kg/m2. Partici-
pants reporting the use of thyroid hormone were older, had a higher BMI, and were more fre-
quently female and obese (BMI >30 kg/m2). They were also less healthy as they had higher
glucose, HbA1c and total cholesterol and triglyceride levels, more frequently had metabolic
syndrome or type 2 diabetes, and used a higher number of medications including statins and
antihypertensive medication.
Thyroid disease based on current and previous medication use
The question on current use of medication for an underactive or overactive thyroid was
answered positively by 4579 participants (3.0% of total). The majority of them (96.4%)
reported the use of levothyroxine (Table 2). Of those reporting no use of medication, 63
(0.04%) did use thyroid medication according to the verification of the medication list, again
the majority using levothyroxine. An answer to this question was missing in 3731 participants,
as this question was not part of the proxy questionnaire. Still, 236 (6.3%) of them were using
medication according to the verified medication list, bringing the total users of medication to
4790 (= 3.1% of the total population). In total 118 participants (0.08%) used a thyroid blocker
indicating active treatment for thyrotoxicosis.
A total of 3169 participants reported at baseline that they have used medication for an
underactive or overactive thyroid in the past. Of these, 1800 (56.8%) were still using any type
of thyroid medication at the baseline visit according to the verified medication list. This indi-
cates the low discriminatory power of this question to indicate earlier but not current use of
any thyroid medication. Fig 1 shows the distribution of levothyroxine use per age group. There
is a clear increase with age, and for all age groups a 1:5 to 1:6 male:female ratio. The overall
prevalence of levothyroxine use was 3.1% (0.9% in men and 4.7% in women).
In Table 3, we compared the incidence and prevalence of hypothyroidism (ICPC code T86)
of the NIVEL G.P. registration with the prevalence of hypothyroidism (defined as levothyrox-
ine use) in Lifelines. The prevalence of hypothyroidism in male participants was similar, but in
females the prevalence of hypothyroidism appeared to be higher in Lifelines for almost all age
groups, except those>85 years. In addition, we compared our data to NHANES. In NHANES
the prevalence of hypothyroidism (defined as any use of thyroid hormone) was higher than
that in Lifelines, especially for individuals >45 years in both males and females.
Thyroid hormone levels
In 39935 participants, thyroid hormone levels were available. For the subsequent analyses, we
excluded users of methimazole, propylthiouracil, animal source of thyroid hormone and/or
PLOS ONE Epidemiology of thyroid disorders
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Fig 1. Percentage of levothyroxine users per age group.
https://doi.org/10.1371/journal.pone.0242795.g001
Table 3. Incidence and prevalence of hypothyroidism (in number per 1000).
Incidence NIVELa Prevalence NIVEL a Prevalence NHANES b Prevalence Lifelines c
Total 4.3 21.8 unknown unknown
Age group Males Females Males Females Males Females Males Females
0–4 yrs 0.3 0.1 1 0.6 NA NA NA NA
5–17 yrs 0.3 0.8 1 2.6 NA NA NA NA
18–44 yrs 0.9 5.1 3.5 22.1 3.5 31.0 5.1 29.8
45–64 yrs 2.3 9.3 10.3 51.4 25.0 113.1 10.5 58.7
65–74 yrs 4.2 123 18.4 74 49.0 118.7 17.8 95.3
75–84 yrs 5.4 14.9 26.4 77.5 112.5 214.0 30.9 113.7
�85 yrs 8.5 14.8 30.5 73.4 NA NA 28.2 60.8
Sources:
a Open access NIVEL Registration of Care by G.P.’s, accessed March 2014, based on diagnosis code T86, registered by a G.P.
b,c Based on use of thyroid hormone supplementation.
https://doi.org/10.1371/journal.pone.0242795.t003
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liothyronine (n = 76). Participants using levothyroxine had higher FT4 and lower FT3 com-
pared to those not using levothyroxine, with comparable TSH concentrations (S2 Table).
As shown in Table 4, prevalence of abnormal thyroid hormone levels in those not using thy-
roid medication was 10.8%; 9.4% had a mildly elevated TSH level (4.01–10.0 mIU/L, subclini-
cal hypothyroidism), 0.7% had a suppressed TSH level (<0.4 mIU/L), while 0.7% had elevated
TSH (>10 mIU/L, overt hypothyroidism). Fig 2 shows the inverse relationship between TSH
and FT4 levels in individuals with elevated TSH (>4.0 mIU/L) not using levothyroxine. In
total, 3600 of 3660 participants (98.4%) with TSH between 4.01 and 10.0 mIU/L still had a nor-
mal FT4 (>11.0 pmol/L). Of those with TSH >10.0 mIU/L, 61% had FT4 levels within the ref-
erence range. In participants using levothyroxine, less than 60% had TSH levels within the
reference range of 0.40–4.0 mIU/L, 13.7% had suppressed TSH, while 27.0% had elevated TSH
levels (Table 4). Prevalence of suppressed TSH gradually increased with increasing age in non-
users (Table 5). With the exception of the high prevalence of subclinical hypothyroidism in
those aged 18–29 years (13%), there is also a gradual increase of prevalence of subclinical hypo-
thyroidism with ageing. For comparison, S3 Table shows similar data for NHANES. Com-
pared to Lifelines, NHANES observed an overall higher prevalence of suppressed TSH,
whereas the percentage of individuals with mildly or severely elevated TSH was lower.
Validation of self-reported thyroid disorders and / or surgery
A total of 282 participants answered in question HEALTH73 that they had a thyroid disorder
(S4 Table). Only 49 of them had answered ‘yes’ to either question HEALTH66 or HEALTH67
related to medication use for an overactive or underactive thyroid. The majority reported
hypothyroidism. Considering the large difference between this question HEALTH73 and
questions HEALTH66/67, these data must be considered as incomplete. A total number of 674
participants (0.4%) reported in the open question on surgery (HEALTH74) that they previ-
ously had undergone thyroid surgery (S4 Table). Over 50% reported no specific reason for
their surgery.
S5 Table shows the number of participants reporting a new thyroid disorder in one of the
follow-up questionnaires (question HEALTH100). Hypothyroidism and an unspecified thy-
roid disorder (the participant did not specify the nature of the thyroid disorder) were reported
most frequently. Based on the number of participants and the duration of follow-up, this
would suggest an incidence of hypothyroidism between 1.6 and 2.3 per 1000 individuals per
year, and a total incidence of thyroid disorders of 3.1 per 1000 individuals per year. These inci-
dence data are considerably lower than the incidence of hypothyroidism as collected by Dutch
G.P.’s (Table 3). Unfortunately, the development of new thyroid disorders reported by Life-
lines participants could not be checked with G.P. datasets or new medication use. However, in
the subgroup of participants with available TSH levels at baseline, we were able to ascertain
Table 4. Distribution of TSH class in participants according to levothyroxine use�.
No levothyroxine Levothyroxine
All M F All M F
TSH <0.4 mIU/L 265 (0.7%) 91 174 155 (13.7%) 17 138
TSH 0.4–4.0 mIU/L 34545 (89.2%) 14825 19720 670 (59.3%) 68 602
TSH 4.01–10.0 mIU/L 3660 (9.4%) 1169 2491 254 (22.5%) 31 223
TSH�10.0 mIU/L 266 (0.7%) 77 189 51 (4.5%) 12 39
Total (n) 38736 16162 22574 1130 128 1002
�Participants reporting the use of thyroid blockers (methimazole or propylthiouracil), liothyronine, animal source thyroid hormone and amiodarone were excluded.
https://doi.org/10.1371/journal.pone.0242795.t004
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how many individuals with a substantially elevated TSH level at baseline reported a new thy-
roid disorder during one of the follow-up questionnaires. Of the 70 participants with TSH
level> 20.0 mIU/L without using thyroid hormone at baseline, only 18 reported the develop-
ment of a new thyroid disorder. Reversely, we calculated that of 236 participants who reported
a new hypothyroidism during follow-up, 119 (50.4%) were already using thyroid hormone
supplementation at baseline.
Fig 2. Relationship between TSH and FT4 in participants with subclinical or overt hypothyroidism not using levothyroxine. The line indicates the linear
regression relationship. Note that 98.4% of the individuals with a TSH between 4.01 and 10.0 mIU/L had a normal FT4 concentration (>11 pmol/L).
https://doi.org/10.1371/journal.pone.0242795.g002
Table 5. Distribution of TSH class per age group (in %) in participants not using thyroid medication or amiodarone at baseline.
TSH levels (mIU/L)
Age group (years) N <0.40 0.40–4.0 4.01–10.0 >10.0
18–29 5111 0.4 86.1 13.0 0.5
30–39 8017 0.5 92.2 6.7 0.6
40–49 13365 0.7 91.0 7.7 0.6
50–59 6793 0.7 88.0 10.3 1.0
60–69 4253 1.1 84.9 13.2 0.8
70–79 1084 1.1 84.0 13.9 1.0
�80 113 6.2 77.0 16.8 0.0
https://doi.org/10.1371/journal.pone.0242795.t005
PLOS ONE Epidemiology of thyroid disorders
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Discussion
Prevalence of thyroid disorders based on use of thyroid medication
In the Lifelines Cohort Study, we showed that the overall prevalence of diagnosed and treated
thyroid disorders (hypothyroidism plus thyrotoxicosis), assessed by medication use, is 3.1%.
Compared to the NIVEL G.P. registration, the prevalence of hypothyroidism (defined as
levothyroxine supplementation) in male Lifelines participants was similar. In females the prev-
alence of hypothyroidism appeared to be higher. Thyroid hormone measurements in a subset
of almost 40000 participants showed that the prevalence of unknown / undetected subclinical
hypothyroidism was 9.4%, while the prevalence of undetected overt hypothyroidism was 0.7%.
As expected, the use of levothyroxine increased with age. However, only 59.3% of users of
levothyroxine had a TSH level within the normal range, meaning that possibly a large propor-
tion is being undertreated (TSH >4.0 mIU/L, 27%) or overtreated (TSH<0.4 mIU/L, 13.7%).
In comparison with the NIVEL G.P. registrations, the estimated prevalence of hypothyroid-
ism in Lifelines was similar in men, but in women it was higher except in those>85 years.
This difference may be a consequence of the different way how hypothyroidism was defined,
i.e. ICPC T86 coding (NIVEL) versus use of levothyroxine (Lifelines). Also, the time period in
which data have been collected differed slightly, i.e. 2007–2013 in Lifelines, and 2013 in the
NIVEL / G.P. registration. It should be noted that there is very limited information on how
well hypothyroidism is diagnosed and scored in general practice. Research by NIVEL indicated
that slightly over 80% of patients using thyroid hormone had a concomitant T86 ICPC code
(registered hypothyroidism / myxoedema) [28]. The assumption that over 90% of levothyrox-
ine users have this medication prescribed because of primary hypothyroidism may lead to the
conclusion that there is a 10% underreporting. In addition, a recent report on the conse-
quences of the temporary withdrawal of the ThyraxR brand from the Dutch market mentioned
that about 8% of levothyroxine users only used a dose of 25 mcg per day or less [29], suggesting
that a considerable number of patients labelled with ICPC code T86 had subclinical and not
overt hypothyroidism. This may also apply to the Lifelines dataset.
Prevalence and incidence of thyroid disorders based on thyroid hormone
levels
In Lifelines participants, a new diagnosis of overt hypothyroidism (TSH>10.0 mIU/L) was
made in 0.7%, while the prevalence of subclinical hypothyroidism was 9.4%. A significant
number (61%) of participants with TSH>10.0 mIU/L still had normal FT4 levels. Over the
previous decades, the (reported) prevalence of thyroid disease has changed. One of the first
studies to evaluate thyroid function on a large scale in the population was the Whickham Sur-
vey, which was conducted between 1972 and 1974 [30]. The prevalence of established hypothy-
roidism was 1.4% in women and 0.1% in men. Five new cases of overt hypothyroidism were
found (0.35%), while prevalence of elevated TSH (defined as�6.0 mIU/L) was 7.5% in women
and 2.8% in men [30]. It must be realized that in those days, treatment was different (thyranon,
thyroid powder), and immunoassays were less developed. In 1985, the Framingham study
reported that the prevalence of hypothyroidism was 4.4% (95/2139 participants over the age of
60 years), with a higher prevalence in women (5.9%) compared to men (2.4%). Prevalence of
subclinical hypothyroidism (defined as TSH 5.0–10.0 mIU/L) was 5.9% [31]. In a follow-up
study of the Whickham Survey, the incidence of hypothyroidism was calculated to be 3.5 per
1000 per year in women and 0.6 per 1000 per year in men [32]. Other studies, summarized by
Vanderpump in an extensive review in 2011, reported a prevalence of previously undiagnosed
overt hypothyroidism between 0 and 7.8 per 1000 men, and 3.0 and 20.5 per 1000 women [33].
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Data from 1995–1997 in Norway were similar, with a prevalence of treated hypothyroidism
of 4.8% in women and 0.89% in men, and a clear increase of prevalence with higher age [34].
In addition, the prevalence of undiagnosed hypothyroidism (TSH�10.0 mIU/L) was 0.9% in
women and 0.37% in men, while the prevalence of subclinical hypothyroidism was 5.1 and
3.7%, respectively [34]. In a follow-up study between 2006–2008 from HUNT, the prevalence
of undiagnosed overt as well as subclinical hypothyroidism had declined considerably, while
the prevalence of treated hypothyroidism had increased from 5.0 to 8.0% in women, and from
1.0 to 2.0% in men [2]. The explanation of the investigators for these changes were increased
thyroid function testing as well as earlier levothyroxine treatment for subclinical hypothyroid-
ism [2]. A similar trend was observed between 2000 and 2010 surveys in Pomerania [35]. This
may suggest that a significant number of individuals is treated with thyroid hormone supple-
mentation without possible medical necessity [36]. Over 60% of individuals in whom subclini-
cal hypothyroidism is established, thyrotropin declines to the normal range over 5 years [36].
Too liberal thyroid hormone treatment in individuals with moderately elevated TSH levels
may be one of the factors responsible for differences in medication use between studies. This
trend could also be observed in the Thyroid Epidemiology Audit and Research Study (TEARS)
in Tayside, UK, where almost half of the individuals who started taking thyroid hormone sup-
plementation had a TSH level<6.0 mIU/L [37]. Similar mechanisms may explain the higher
prevalence of levothyroxine use between NHANES and Lifelines (Table 3).
Other reasons for the difference in prevalence may be differences in reference values. One
study in Korea based its reference values for TSH, measured with similar methodology as in
our present study, on the 2.5th and 97.5th percentile of TSH values in subjects with no prior his-
tory of thyroid disease, no family history of disease, negative TPO-antibodies, and serum FT4
levels in the reference range [38]. This yielded a reference value for TSH from 0.62 to 6.86
mIU/L, which significantly lowers the percentage of individuals with subclinical hypothyroid-
ism compared to our reference values. A study in France suggested the use of age-specific and
sex-specific reference values for TSH, with upper-limit reference values>5.0 mIU/L for
women over the age of 70 [39]. This might partly explain the large number of individuals with
a normal FT4 in combination with a slightly elevated TSH in the current study.
Prevalence of abnormal TSH levels in individuals using levothyroxine
Previous research has clearly shown that -with TSH levels in the normal range- FT4 levels
were significantly higher and yet FT3 levels were significantly lower (p<0.001 in both cases) in
levothyroxine-treated athyreotic patients than in matched euthyroid control subjects [40]. In
Lifelines participants using levothyroxine, only 59.3% had TSH levels within the normal range,
while 27% had a TSH > 4.0 mIU/L and appeared to be undertreated, and 13.7% had a sup-
pressed TSH level and was possibly overtreated. Similarly, in 2000 the Colorado Thyroid Dis-
ease Prevalence Study reported that 60% of individuals using thyroid medication had a normal
TSH level [41]. The same study reported that the percentage of participants taking thyroid
medication with subclinical hyperthyroidism (TSH between 0.01–0.3 mIU/L) was 20%, while
17% had subclinical hypothyroidism (TSH >5.1 mIU/L and total T4>57.9 nmol/L) [41]. Sim-
ilar data were reported in the UK and Brasil, with the latter study showing poorer health-
related quality of life associated with undertreatment [42, 43]. A recent study in The Nether-
lands evaluating a levothyroxine brand switch amongst individuals with hypothyroidism
treated in general practice showed that 67% of participants had a TSH level within the refer-
ence range [29]. The reasons for this are not clear. On the one hand, doctors may ignore the
significance of elevated TSH levels when concomitant measurements show an FT4 level within
the normal range. On the other hand, it may well be that despite an elevated TSH,
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levothyroxine dose is not increased when patients do not report any complaints. TSH levels
may vary over time, however, and a G.P. may decide not to alter the dose when the previous
TSH level was within the target. The Dutch guidelines for G.P.’s nevertheless mention that
with optimal supplementation, TSH is in the low-normal range of 0.5–2.0 mIU/L, and FT4
then is ‘high-normal’ [44].
Validity of the obtained thyroid data
The extensive set of data collected by Lifelines supports its merits for thyroid-oriented
research. Previously we have reported in smaller-sized studies based on baseline Lifelines data
on the relationship between thyroid hormone levels and health-related quality of life [13], and
metabolic syndrome [18], and the effect of the Thr92Ala polymorphism on thyroid function
and health-related quality of life [21]. Also, in Lifelines genome-wide association study
(GWAS) studies have been performed in over 13000 participants, and Lifelines data have con-
tributed to several genetic evaluations including those related to thyroid function [45, 46].
Because of the longitudinal design, the Lifelines study may offer additional opportunities
to expand our knowledge on the natural course of (subclinical) hypothyroidism and its
complications. We observed a 0.7% prevalence of elevated TSH >10 mIU/L within the sub-
set of Lifelines’ participants not using thyroid medication with thyroid function measured.
This implies that approximately 800 of the 112000 Lifelines participants in whom thyroid
hormone was not measured, a TSH level >10.0 mIU/L could have been found. At follow-
up, at least 778 new diagnoses of hypothyroidism and 317 unspecified thyroid disorders
have been reported by participants (S5 Table). Also, 3660 participants had a TSH level
between 4.0 and 10.0 mIU/L. Considering the current collection of information of Lifelines
participants, these further investigations should be done in substudies in which additional
data are collected, and verification of diagnosis and medication through G.P.’s charts and
pharmacists’ prescription data is indicated. Also, to better classify the relevance of subclini-
cal hypothyroidism, measurement of anti-TPO antibodies would be of value. Currently
such connections are being made, bringing an integrated big data approach where biobanks
and clinical datasets are connected [47].
At baseline, one of the most important sources for establishing diagnoses and co-morbidi-
ties was the list of medication used by a participant. Medication has been shown to be a power-
ful indicator for (co-)morbidity [48, 49], health-related quality of life, and even severity of
disease [50, 51]. Also the studies in Tayside, UK, considered medication use as the most
important source for classifying participants with thyroid dysfunction [37]. Unfortunately, no
data are available on the use of new medications or changes in medication at follow-up in Life-
lines. Medication use like levothyroxine or methimazole can validate the self-reported diagno-
sis of hypothyroidism and thyrotoxicosis, or even ascertain the presence of a thyroid disorder
when a participant did not report this correctly in the questionnaire. However, it must be
noted that thyroid hormone supplementation is prescribed both in case of primary and sec-
ondary hypothyroidism. From the current dataset, we could not differentiate between these
two causes, although epidemiologic data suggest that the majority of levothyroxine use is for
primary hypothyroidism, either Hashimoto’s hypothyroidism or hypothyroidism after treat-
ment of thyrotoxicosis with surgery or radioactive iodine. Concomitant use of for instance
hydrocortisone, sex hormones like testosterone and / or growth hormone could suggest the
presence of secondary hypothyroidism. However, pituitary insufficiency comes in many vari-
ants, and also primary hypothyroidism and primary adrenal insufficiency (in case of hydrocor-
tisone use) do co-exist. Adequate differentiation between both variants of hypothyroidism
should therefore also be done by verification of G.P.’s charts.
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Strengths and limitations
Our study has several strengths and weaknesses. We presented baseline data on 152180 partici-
pants within a broad range of age and comorbidities, and the results of thyroid function in one
of the largest population-based thyroid hormone screenings available, with extensive phenotyp-
ing in several domains of health and disease. Limitations are mainly found in the question-
naires. The Lifelines open text questions at baseline allowed participants to report whether they
had undergone thyroid surgery, and the follow-up questionnaires allowed to report whether
they had developed a new thyroid disorder. Both proved not to be reliable and severely underes-
timate the true incidence and prevalence of thyroid disorders. The number of answers to the
question HEALTH73 (Do you have or have you had another disorder that you have not men-
tioned yet?) is only a fraction of the number of individuals who were using thyroid hormone
supplementation. By extrapolation, we assume that the same holds true for the question regard-
ing previous surgery for a thyroid disorder (HEALTH74). The majority of answers (55%) just
mentioned thyroid surgery without any details on cause or type of procedure. In agreement
with advices described in a 2009 editorial [52], the Lifelines questionnaires specifically ask for
the history of several diseases as recognized and recalled by the patient, for instance several
types of cardiovascular disease, osteoporosis, diabetes, hypertension, cancer, rheumatoid arthri-
tis and inflammatory bowel diseases. However, the only specific questions asking for a thyroid
disorder are the questions on current (HEALTH66) and past (HEALTH67) use of medication
for a thyroid disorder. Even when such a specific question is introduced in future question-
naires, we can discuss how well they will be answered. Over half of the participants who
reported earlier use of thyroid medication still was using medication at baseline screening. In
addition, 10% of participants who answered that they underwent thyroid surgery, reported a
cyst as a reason for surgery, which is not current practice in our country. Also, only a limited
number of the participants who were found to have severely elevated TSH levels at baseline
screening, reported a new thyroid disorder in one of the follow-up questionnaires. It should be
noted that all TSH levels>10.0 mIU/L were communicated with the G.P. of a participant, with
the advice (depending on the level of TSH) to re-check if needed, and otherwise to start
levothyroxine supplementation. As mentioned earlier, validation of diagnoses and previous sur-
gical procedures can be realised by exchanging data with charts of G.P.’s practices, and by col-
lecting surgical notes from hospital charts. Lifelines is in an excellent position to increase its
value and significance this way, especially because all health-related information is collected in
the practice of the G.P., who plays a central role in the Dutch health care system.
Conclusion
The population prevalence of treated thyroid disorders in Lifelines is 3.1%. In those not
known to have a thyroid disorder, the prevalence of primary hypothyroidism is 0.7%, and of
subclinical hypothyroidism is 9.4%. Furthermore, 0.7% has a suppressed TSH. Only 59.3% of
those participants who use levothyroxine have a TSH level in the normal range. Reliable ascer-
tainment of previous and new thyroid disorders is not possible based on the currently used
questionnaires. The large group of individuals with subclinical hypothyroidism offers an excel-
lent possibility to prospectively follow the natural course of this disorder. However, both struc-
tured questions as well as linking to G.P.’s and pharmacists’ data are necessary to improve the
completeness and reliability of data on thyroid disorders.
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